Literature DB >> 18615663

Advanced bladder cancer: so many drugs, so little progress : what's wrong with this picture?

Robert Dreicer.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18615663     DOI： 10.1002/cncr.23690

Source DB:  PubMed          Journal:  Cancer        ISSN： 0008-543X            Impact factor:   6.860


× No keyword cloud information.
  4 in total

Review 1.  Urothelial carcinoma of the bladder: definition, treatment and future efforts.

Authors:  Sandip M Prasad; G Joel Decastro; Gary D Steinberg
Journal:  Nat Rev Urol       Date:  2011-10-11       Impact factor: 14.432

2.  miR-200 expression regulates epithelial-to-mesenchymal transition in bladder cancer cells and reverses resistance to epidermal growth factor receptor therapy.

Authors:  Liana Adam; Meng Zhong; Woonyoung Choi; Wei Qi; Milena Nicoloso; Ameeta Arora; George Calin; Hua Wang; Arlene Siefker-Radtke; David McConkey; Menashe Bar-Eli; Colin Dinney
Journal:  Clin Cancer Res       Date:  2009-08-11       Impact factor: 12.531

3.  miR-200c inhibits invasion, migration and proliferation of bladder cancer cells through down-regulation of BMI-1 and E2F3.

Authors:  Lei Liu; Mingning Qiu; Guobin Tan; Ziji Liang; Yue Qin; Lieqian Chen; Hege Chen; Jianjun Liu
Journal:  J Transl Med       Date:  2014-11-04       Impact factor: 5.531

4.  ADAM15 Is Functionally Associated with the Metastatic Progression of Human Bladder Cancer.

Authors:  Guadalupe Lorenzatti Hiles; Amanda Bucheit; John R Rubin; Alexandra Hayward; Angelica L Cates; Kathleen C Day; Layla El-Sawy; L Priya Kunju; Stephanie Daignault; Cheryl T Lee; Monica Liebert; Maha Hussain; Mark L Day
Journal:  PLoS One       Date:  2016-03-01       Impact factor: 3.240
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.